Sensient board member Dr. Elaine Wedral to retire; Kathleen Da Cunha nominated

SENSIENT TECHNOLOGIES CORP

Dr. Elaine Wedral will retire from the Board at the end of her term at the 2023 annual meeting; decision not due to any disagreement.
Wedral served since 2006, including as Chair of the Scientific Advisory Committee and first Lead Director (2014-2017).
Board intends to nominate Kathleen Da Cunha for election at the 2023 annual meeting of shareholders.
Da Cunha is SVP of R&D and Strategy at Ruiz Foods, with experience in food/beverage and personal care markets.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dr. Elaine Wedral

Director

SXT · SENSIENT TECHNOLOGIES CORP

Successor: Kathleen Da Cunha
Filed: December 9, 2022, 6:59 PM ET

Dr. Elaine Wedral notified the Board of Directors (the "Board") of Sensient Technologies Corporation (the "Company") that she does not intend to seek reelection and will retire from the Board at the end of her current term expiring at the 2023 annual meeting of shareholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Dr. Elaine Wedral departed as Director at SENSIENT TECHNOLOGIES CORP.

Action: retire
Role: Director

Exact text from the filing

Dr. Elaine Wedral notified the Board of Directors (the "Board") of Sensient Technologies Corporation (the "Company") that she does not intend to seek reelection and will retire from the Board at the end of her current term expiring at the 2023 annual meeting of shareholders.

View on SEC.gov

SENSIENT TECHNOLOGIES CORP filing history →

Source: SEC EDGAR

accession 0001140361-22-045116

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.